Body mass index predicts failure of surgical management in benign prostatic hyperplasia

Urologia Internationalis

Volumn 90, Issue 2, 2013, Pages 150-155

  Willder, Jennifer M ^a,c   Walker, Victoria C ^a   Halbert, Gwen L ^b   Dick, Craig P C ^b   Orange, Clare ^b   Qayyum, Tahir ^a   Horgan, Paul G ^c   Underwood, Mark A ^d   Edwards, Joanne ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Benign prostatic hyperplasia; Body mass index; Inflammation; Lower urinary tract symptoms

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DRUG USE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REOPERATION; TRANSURETHRAL RESECTION; TREATMENT FAILURE; TREATMENT OUTCOME; WEIGHT REDUCTION;

AGED; ASPIRIN; BODY MASS INDEX; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; PROGNOSIS; PROSTATIC HYPERPLASIA; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84874485508     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000345440     Document Type: Article

References (26)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479
2. Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D: Components of the metabolic syndrome -risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998; 1: 157-162
3. Giovannucci E, Rimm EB, Chute CG, Kawachi I, Colditz GA, Stampfer MJ, Willett WC: Obesity and benign prostatic hyperplasia. Am J Epidemiol 1994; 140: 989-1002
4. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW: Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002; 168: 599-604
5. Lee RK, Chung D, Chughtai B, Te AE, Kaplan SA: Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms. BJU Int 2012; 110: 540-545
6. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman P, Antvelink CM, Penson DF, Thompson IM: Race/ethnicity, obesity, health-related behaviors and the risk of symptomatic benign prostatic hyperplasia: Results from the Prostate Cancer Prevention Trial. J Urol 2007; 177: 1395-1400
7. Seim A, Hoyo C, Ostbye T, Vatten L: The prevalence and correlates of urinary tract symptoms in Norwegian men: The Hunt Study. BJU Int 2005; 96: 88-92
8. Lotti F, Corona G, Colpi GM, Filimberti E, Degli Innocenti S, Mancini M, Baldi E, Noci I, Forti G, Adorini L, Maggi M: Elevated body mass index correlates with higher seminal plasma interleukin-8 levels and ultrasonographic abnormalities of the prostate in men attending an andrology clinic for infertility. J Endocrinol Invest 2011; 34:e336-e342
9. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, Landis P, Platz EA: Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006; 91: 2562-2568
10. Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, Castellanos R, Coffield S, Saltzman B, Resnick M, Cook TJ, Waldstreicher J: Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999; 53: 473-480
11. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-2398
12. De Heredia FP, Gomez-Martinez S, Marcos A: Obesity, inflammation and the immune system. Proc Nutr Soc 2012; 71: 332-338
13. St Sauver JL, Sarma AV, Jacobson DJ, McGree ME, Lieber MM, Girman CJ, Nehra A, Jacobsen SJ: Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. Am J Epidemiol 2009; 169: 1281-1290
14. Khoo J, Piantadosi C, Duncan R, Worthley SG, Jenkins A, Noakes M, Worthley MI, Lange K, Wittert GA: Comparing effects of a low-energy diet and a high-protein low-fat diet on sexual and endothelial function, urinary tract symptoms, and inflammation in obese diabetic men. J Sex Med 2011; 8: 2868-2875
15. Alokail MS, Al-Daghri NM, Al-Attas OS, Alkharfy KM, Sabico SB, Ullrich A: Visceral obesity and inflammation markers in relation to serum prostate volume biomarkers among apparently healthy men. Eur J Clin Invest 2011; 41: 987-994
16. Shafique K, Proctor MJ, McMillan DC, Qureshi K, Leung H, Morrison DS: Systemic inflammation and survival of patients with prostate cancer: Evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis 2012; 15: 195-201
17. Klintrup K, Makinen JM, Kauppila S, Vare PO, Melkko J, Tuominen H, Tuppurainen K, Makela J, Karttunen TJ, Makinen MJ: Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005; 41: 2645-2654
18. Li MK, Garcia L, Patron N, Moh LC, Sundram M, Leungwattanakij S, Pripatnanont C, Cheng C, Chi-Wai M, Loi-Cheong N: An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function. BJU Int 2008; 101: 197-202
19. Lee SH, Oh CY, Park KK, Chung MS, Yoo SJ, Chung BH: Comparison of the clinical efficacy of medical treatment of symptomatic benign prostatic hyperplasia between normal and obese patients. Asian J Androl 2011; 13: 728-731
20. Emberton M, Neal DE, Black N, Harrison M, Fordham M, McBrien MP, Williams RE, McPherson K, Devlin HB: The National Prostatectomy Audit: The clinical management of patients during hospital admission. Br J Urol 1995; 75: 301-316
21. Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer B, Gessl A, Lee C, Marberger M: Increased expression of lymphocytederived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002; 52: 43-58
22. Qayyum T, McArdle PA, Going JJ, Orange C, Seywright M, Aitchison MA, Edwards J: Is the presence or absence of tumour necrosis a significant predictor of survival in renal cell cancer? Urol Int 2012; 88: 79-83
23. Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC: Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. Eur J Cancer 2009; 45: 2138-2145
24. Lamb AD, Qadan M, Roberts S, Timlin H, Vowler SL, Campbell FM, Grigor K, Bartlett JM, McNeill SA: CD4+ and CD8+ T-lymphocyte scores cannot reliably predict progression in patients with benign prostatic hyperplasia. BJU Int 2011; 108:E43-E50
25. Robert G, Descazeaud A, Nicolaiew N, Terry S, Sirab N, Vacherot F, Maille P, Allory Y, de la Taille A: Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysis. Prostate 2009; 69: 1774-1780
26. Selvin E, Paynter NP, Erlinger TP: The effect of weight loss on C-reactive protein: A systematic review. Arch Intern Med 2007; 167: 31-39